Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding

Trial Profile

An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Vilaprisan (Primary)
  • Indications Uterine leiomyoma
  • Focus Adverse reactions; Registrational
  • Acronyms ASTEROID 8
  • Sponsors Bayer
  • Most Recent Events

    • 18 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 20 Aug 2018 Planned End Date changed from 10 Nov 2020 to 27 Mar 2020.
    • 20 Aug 2018 Planned primary completion date changed from 10 Nov 2020 to 27 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top